Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 30;61(9):3657-3666.
doi: 10.1093/rheumatology/keab943.

Evaluation of lupus anticoagulant, damage, and remission as predictors of pregnancy complications in systemic lupus erythematosus: the French GR2 study

Maddalena Larosa  1   2 , Véronique Le Guern  1 , Gaëlle Guettrot-Imbert  1 , Nathalie Morel  1 , Noémie Abisror  3 , Chafika Morati-Hafsaoui  4 , Pauline Orquevaux  5 , Elisabeth Diot  6 , Andrea Doria  2 , Françoise Sarrot-Reynauld  7 , Nicolas Limal  8 , Viviane Queyrel  9 , Odile Souchaud-Debouverie  10 , Laurent Sailler  11 , Maëlle Le Besnerais  12 , Tiphaine Goulenok  13 , Anna Molto  14   15 , Emmanuelle Pannier-Metzger  16 , Loic Sentilhes  17 , Luc Mouthon  1   18 , Estibaliz Lazaro  19 , Nathalie Costedoat-Chalumeau  1   15 ; GR2 Group
Collaborators, Affiliations

Evaluation of lupus anticoagulant, damage, and remission as predictors of pregnancy complications in systemic lupus erythematosus: the French GR2 study

Maddalena Larosa et al. Rheumatology (Oxford). .

Abstract

Objectives: The specific roles of remission status, lupus low disease activity state (LLDAS), and damage accrual on the prognosis of pregnancies in women with SLE are unknown. We analysed their impact on maternal flares and adverse pregnancy outcomes (APOs).

Methods: We evaluated all women (≥18 years) with SLE enrolled in the prospective GR2 study with an ongoing singleton pregnancy at 12 weeks (one pregnancy/woman). Several sets of criteria were used to define remission, disease activity and damage. APOs included: foetal/neonatal death, placental insufficiency with preterm delivery and small-for-gestational-age birth weight. First trimester maternal and disease features were tested as predictors of maternal flares and APOs.

Results: The study included 238 women (98.3% on hydroxychloroquine (HCQ)) with 230 live births. Thirty-five (14.7%) patients had at least one flare during the second/third trimester. At least one APOs occurred in 34 (14.3%) women. Hypocomplementemia in the first trimester was the only factor associated with maternal flares later in pregnancy (P=0.02), while several factors were associated with APOs. In the logistic regression models, damage by SLICC-Damage Index [odds ratio (OR) 1.8, 95% CI: 1.1, 2.9 for model 1 and OR 1.7, 95% CI: 1.1, 2.8 for model 2] and lupus anticoagulant (LA, OR 4.2, 95% CI: 1.8, 9.7 for model 1; OR 3.7, 95% CI: 1.6, 8.7 for model 2) were significantly associated with APOs.

Conclusion: LA and damage at conception were predictors of APOs, and hypocomplementemia in the first trimester was associated with maternal flares later in pregnancy in this cohort of pregnant patients mostly with well-controlled SLE treated with HCQ.

Trial registration: ClinicalTrials.gov, https://clinicaltrials.gov, NCT02450396.

Keywords: adverse pregnancy outcome; damage; pregnancy; remission; systemic lupus erythematosus.

PubMed Disclaimer

References

    1. Andreoli L, Bertsias GK, Agmon-Levin N. et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 2017;76:476–85. - PMC - PubMed
    1. Sammaritano LR, Bermas BL, Chakravarty EE. et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol 2020;72:529–56. - PubMed
    1. Mehta B, Luo Y, Xu J. et al. Trends in maternal and fetal outcomes among pregnant women with systemic lupus erythematosus in the united states: a cross-sectional analysis. Ann Intern Med 2019;171:164. - PubMed
    1. Gatto M, Zen M, Iaccarino L, Doria A.. New therapeutic strategies in systemic lupus erythematosus management. Nat Rev Rheumatol 2019;15:30–48. - PubMed
    1. Zen M, Iaccarino L, Gatto M. et al. Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. Ann Rheum Dis 2015;74:2117–22. - PubMed

Publication types

Substances

Associated data